The FDA will review the data for Biogen and Eisai’s anti-amyloid beta protofibril antibody, lecanemab, on an ongoing basis
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.